通过Poloxamer 188进行心脏保护是通过增加内皮氧化产生的介导
bioRxiv : the preprint server for biology
|June 3, 2024
概括
波洛克萨默188 (P188) 通过增加氧化 (NO) 产量来保护心脏免受缺血/反 (I/R) 损伤,而不仅仅是通过稳定细胞膜来保护心脏. 这种新的机制在细胞和动物模型中得到证实,显示P1888.
科学领域:
- 心血管研究研究心血管研究
- 细胞生物学 细胞生物学
- 生物医学工程 生物医学工程
背景情况:
- 缺血/反 (I/R) 损伤是心脏病发病率和死亡率的主要原因.
- 波洛克萨默188 (P188) 是I / R损伤的潜在治疗剂,但其机制尚未完全理解.
- 内皮细胞功能和氧化 (NO) 在P188的保护作用中的作用需要进一步阐明.
研究的目的:
- 在模拟的I/R条件下,研究P188对细胞存活,功能和NO生产的影响.
- 阐明P188心脏保护作用的潜在机制,重点关注NO信号.
- 为了评估P188在隔离的老鼠心脏模型中的ex-vivo心脏保护功效.
主要方法:
- 利用人类诱导多能干细胞 (iPSC) 衍生的心肌细胞 (CMs) 和内皮细胞 (ECs) 来建模I/R损伤.
- 在低氧/低氧化下进行P188治疗后评估CM收缩性和EC NO产量.
- 采用一个孤立的棕色挪威老鼠心脏模型,接受了I / R损伤,有或没有NO抑制,以评估心脏功能和损伤标志物.
主要成果:
- 在低氧/低氧化后,P188显著保留了iPSC-CM收缩功能,并增强了细胞活力.
- 治疗P188显著增加了iPSC-EC中的NO分泌,这表明了一个新的内皮保护机制.
- 在老鼠心脏中,P188改善了心脏功能,并减少了I/R损伤标志物,这种效应被NO抑制消除了.
- 在接受P188.8治疗的非缺血性老鼠心脏中观察到NO产量的剂量依赖性增加.
结论:
- 通过一种新的机制,P188通过增强氧化 (NO) 生产来保护心脏免受I/R损伤.
- 这种NO介导的保护在iPSC衍生的细胞模型和ex-vivo老鼠心脏模型中都很明显.
- P188在减轻I/R损伤相关心脏功能障碍方面显示出显著的治疗潜力,这需要进一步的临床研究.
相关概念视频
Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Antianginal Drugs: Nitrates and β-Blockers
573
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
573
Antihypertensive Drugs: Vasodilators
503
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167


